EMAIL DETAILS

http://wearemadeinny.com/made-in-ny-list/


This is a program from the Mayor’s office. Could be a nice deal flow source and co-investors. Maybe something we could get involved with give our relationships here?


Neil Callahan

Rosemont Seneca Partners

401 Greenwich Street, Suite 300

New York, New York 10013

917-945-9516 (m)

866-749-8879 (f)

www.rosemontsenecatech.com <http://www.rosemontsenecatech.com/>

Confidentiality Warning: This e-mail contains information intended only for the use of the individual or entity named above. If the reader of this e-mail is not the intended recipient or the employee or agent responsible for delivering it to the intended recipient, any dissemination, publication or copying of this e-mail is strictly prohibited. The sender does not accept any responsibility for any loss, disruption or damage to your data or computer system that may occur while using data contained in, or transmitted with, this e-mail.If you have received this e-mail in error, please immediately notify us by return e-mail. Thank you


From: Devon Archer [mailto:darcher@rosemontseneca.com]
Sent: Sunday, February 24, 2013 11:35 AM
To: <ncallahan@rosemontseneca.com>
Cc: John DeLoche; Hunter Biden; Eric Schwerin; Rob Walker
Subject: Re: adult stem cell opp


What's the minimum we could participate at if deemed worthy?

Devon Archer

646 436 3745


On Feb 24, 2013, at 11:30 AM, "Neil Callahan \(Rosemont Seneca\)" <ncallahan@rosemontseneca.com> wrote:

Right, good exposure to an interesting space. Any angle we can propose on the advisory side? Super regulated topic – success or failure hinges on policy and regulation here for sure (i.e., gove research $, insurance coverage for therapies, permissibility of therapies, IP rights/public good, etc.)


Neil Callahan

Rosemont Seneca Partners

401 Greenwich Street, Suite 300

New York, New York 10013

917-945-9516 (m)

866-749-8879 (f)

www.rosemontsenecatech.com <http://www.rosemontsenecatech.com/>

Confidentiality Warning: This e-mail contains information intended only for the use of the individual or entity named above. If the reader of this e-mail is not the intended recipient or the employee or agent responsible for delivering it to the intended recipient, any dissemination, publication or copying of this e-mail is strictly prohibited. The sender does not accept any responsibility for any loss, disruption or damage to your data or computer system that may occur while using data contained in, or transmitted with, this e-mail.If you have received this e-mail in error, please immediately notify us by return e-mail. Thank you


From: John DeLoche [mailto:jdeloche@rosemontseneca.com]
Sent: Sunday, February 24, 2013 11:20 AM
To: Neil Callahan
Cc: Hunter Biden; Eric Schwerin; Devon Archer; Rob Walker
Subject: Fwd: adult stem cell opp


Here is the dataroom access. this may be too capital intensive for us. we need to be respectful to Trent obviously. let's discuss this week.

---------- Forwarded message ----------
From: Trent Gegax <trent.gegax@gramercyfund.com>
Date: Sat, Feb 23, 2013 at 3:42 PM
Subject: Re: adult stem cell opp
To: John DeLoche <jdeloche@rosemontseneca.com>
Cc: Greg Arrese <garrese@scogcap.com>


Sounds good. Here you go. I have permission to pass access to you. Happy wknd.


http://stemedica-casestudies.imagebeam.com/docs

username: smuser

password: u891mnb!


T. Trent Gegax

917.592.1686

www.gramercyfund.com

@gegax


On Feb 23, 2013, at 5:38 PM, "John DeLoche" <jdeloche@rosemontseneca.com> wrote:

Hi Trent,


Thanks for thinking of us. I would like to learn more. Is there a slide deck w financials you could send. Happy to take a look in the data room.


Best,


John

Sent from my iPad


On Feb 23, 2013, at 2:14 PM, Trent Gegax <trent.gegax@gramercyfund.com> wrote:

howdy, john. yesterday my father and I had an interesting update call with one of our life-sciences portfolio cos, san diego-based stemedica <http://www.stemedica.com/> , in the adult stem cell space. they're finishing a big 'rolling raise' and are down to their last 7m (we're considering adding to our position) of their 72m preferred raise (148m pre-money, 220m post-money).


you came to mind because stemedica feels like it's about at the stage that counsyl was at when you introduced it to us, tho it's taken stemedica longer to develop than counsyl (we initially invested in 2007). maybe chalk that up to being in the controversial stem cell space, maybe not.


any rate, let me know if you want access to their data room and, if further interested, i'll intro you to stemedica ceo maynard howe, who started two other life sciences cos that we invested in and that went ipo. my father tom is friends with maynard and has known the prolific howe family for decades.


ceo maynard expects stemedica to be cashflow poz q313; their first big pharma deal to give them a 1b valuation; and midcase valuation in 5 yrs to be 3b. maynard has invested millions of his own money and plans to return all of investors money via dividends within two yrs.


ip is stemedica's edge. the short story on the extension of the current raise is that they had an ip discovery that they decided to button down rather than use raised funds to ramp sales.


interesting recent developments include aggressive interest from tx gov perry, a stem cell fan who wants tx to unseat ca as the stem cell capital of the u.s.; a big addition to the board; and significant jv with leading public life-sciences firm.


let me know if you'd like to see more.


best,

trent


T. Trent Gegax

www.gramercyfund.com

917.592.1686

@gegax


--
John DeLoche

Managing Director

Rosemont Seneca Technology Partners

One Market, Spear Tower, 36th Floor

San Francisco, CA 94105

office: 415 293 8147

mobile: 415 793 7070


This email communication is privileged and confidential and is intended only for the individuals or entities named above. Any unauthorized dissemination of any of the contents of this email is strictly prohibited. If you are not the intended recipient, please do not read, copy, use or disclose to others the contents of this communication. Please notify the sender that you have received this e-mail in error and then delete the e-mail.